Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette

Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette–Guérin

Published:2004-01-01 Issue:4 Volume:38 Page:285-290
ISSN:0036-5599
Container-title:Scandinavian Journal of Urology and Nephrology
language:en
Short-container-title:Scandinavian Journal of Urology and Nephrology

Author:

Andius Patrik¹,Damm Ole²,Holmäng Sten¹

Affiliation:

1. Departments of Urology, Sahlgrenska University Hospital, Göteborg, Sweden

2. Linköping University Hospital, Linköping, Sweden

Publisher

Informa UK Limited

Subject

Urology,Nephrology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365590410028692

Reference16 articles.

1. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol 1994; 157 (Suppl): 147–51.

2. MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG;Urologic Oncology: Seminars and Original Investigations;2022-01

2. Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette–Guérin immunotherapy;Journal of Cancer Research and Clinical Oncology;2019-06-21

3. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinomain situof the urinary bladder;Scandinavian Journal of Urology;2016-08-15

4. Prognostic value of preoperative pyuria in patients with non-muscle-invasive bladder cancer;International Journal of Urology;2015-04-24

5. Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter;Oncotarget;2014-06-30